Today, Friday 10 October, the Fraunhofer Spain Research was officially inaugurated at the Barcelona Science Park (PCB), the result of a strategic collaboration with the Institute for Bioengineering of Catalonia … Read more
Ref: PhD-EE // Deadline: 23/10/2025
Ref: RA-XT // Deadline: 17/10/2025
Ref: SR_SS // Deadline: 15/11/2025
Amaya Hernández-Vega, a senior researcher at IBEC, will lead one of the two projects selected in the 2024 call for proposals from the Pasqual Maragall Research Programme, which is dedicated to funding research into Alzheimer’s disease and other neurodegenerative conditions. IBEC also celebrates the participation of Jordi Duran, an associate researcher from the Molecular and Cellular Neurobiotechnology group, who will collaborate on the second selected project.
An international team co-led by the Institute for Bioengineering of Catalonia (IBEC) and the West China Hospital Sichuan University (WCHSU) was able to reverse Alzheimer’s in mice after only 3 injections with nanoparticles. The innovative approach to treating the disease focuses on restoring the normal function of the vasculature, rather than acting on neurons or other brain cells, as has usually been done until now. This achievement, published in the Signal Transduction and Targeted Therapy Journal, is a promising step towards an effective treatment for Alzheimer’s disease.
The event, jointly organised by the Institute for Bioengineering of Catalonia (IBEC) and the Institut Químic de Sarrià (IQS), brought together leading scientists from around the world to discuss the latest advances in blood-brain barrier (BBB) research, from its fundamental biology to its role in disease and therapeutic strategies.